Nevi and melanoma in the pregnant woman

被引:20
作者
Driscoll, Marcia S. [2 ]
Grant-Kels, Jane M. [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Dept Dermatol, Farmington, CT 06030 USA
[2] Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA
关键词
CUTANEOUS MALIGNANT-MELANOMA; ORAL-CONTRACEPTIVE USE; SPECTROPHOTOMETRIC INTRACUTANEOUS ANALYSIS; STAGE-IV MELANOMA; TERM-FOLLOW-UP; MELANOCYTIC NEVI; REPRODUCTIVE FACTORS; WOMEN; MANAGEMENT; HORMONES;
D O I
10.1016/j.clindermatol.2008.09.009
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Multiple difficult questions arise when a pregnant woman presents to the dermatologist with a changing melanocytic nevus or melanoma. Our review of the literature provides some insight into these issues. We recommend that a changing pigmented lesion in the pregnant woman should be biopsied promptly and can be safely performed. Women who have dysplastic nevus syndrome require closer monitoring during pregnancy. For the pregnant woman with a confirmed, localized melanoma, prognosis does not appear to be affected by pregnancy. Likewise, limited data indicate that pregnancy before or after a diagnosis of melanoma does not affect prognosis. Wide local excision may be performed safely, but if sentinel lymph node mapping and biopsy is indicated, the technique and safety of this procedure in the pregnant woman remains controversial. There appears to be no absolute contraindication to the prescription of oral contraceptive pills or hormone replacement therapy in someone who has been previously diagnosed with melanoma if no reasonable alternative exists. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:116 / 121
页数:6
相关论文
共 56 条
[1]   Dermoscopy is a suitable method for the observation of the pregnancy-related changes in melanocytic nevi [J].
Aktuerk, A. S. ;
Bilen, N. ;
Bayraemguerler, D. ;
Demirsoy, E. O. ;
Erdogan, S. ;
Kiran, R. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 (08) :1086-1090
[2]   The benefits and limitations of sentinel lymph node biopsy [J].
Amersi F. ;
Hansen N.M. .
Current Treatment Options in Oncology, 2006, 7 (2) :141-151
[3]   ORAL-CONTRACEPTIVE USE AND MALIGNANT-MELANOMA IN AUSTRALIA [J].
BERAL, V ;
EVANS, S ;
SHAW, H ;
MILTON, G .
BRITISH JOURNAL OF CANCER, 1984, 50 (05) :681-685
[4]   MALIGNANT-MELANOMA AND ORAL-CONTRACEPTIVE USE AMONG WOMEN IN CALIFORNIA [J].
BERAL, V ;
RAMCHARAN, S ;
FARIS, R .
BRITISH JOURNAL OF CANCER, 1977, 36 (06) :804-809
[5]   Special considerations for stage IV melanoma during pregnancy [J].
Beyeler, M ;
Hafner, J ;
Beinder, E ;
Fauchêre, JC ;
Stoeckli, SJ ;
Fehr, M ;
Dummer, R .
ARCHIVES OF DERMATOLOGY, 2005, 141 (09) :1077-1079
[6]  
BYRD B F Jr, 1954, South Med J, V47, P196
[7]  
Campbell FA, 2006, ARCH DERMATOL, V142, P393, DOI 10.1001/archderm.142.3.393-a
[8]   MALIGNANT MELANOMA + PREGNANCY - REPORT OF 3 CASES [J].
CONYBEARE, RC .
OBSTETRICS AND GYNECOLOGY, 1964, 24 (03) :451-&
[9]   Pregnancy and early-stage melanoma [J].
Daryanani, D ;
Plukker, JT ;
De Hullu, JA ;
Kuiper, H ;
Nap, RE ;
Hoekstra, HJ .
CANCER, 2003, 97 (09) :2248-2253
[10]   Hormones, nevi, and melanoma: An approach to the patient [J].
Driscoll, Marcia S. ;
Grant-Kels, Jane M. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 57 (06) :919-931